Skip to main content
. Author manuscript; available in PMC: 2026 Jul 8.
Published in final edited form as: Lancet Neurol. 2026 Jun;25(6):581–590. doi: 10.1016/S1474-4422(26)00123-7

Table 1:

Demographic information for the discovery cohort

Control participants (n=5050) Total case participants (n=101) Case participants with an APP mutation (n=15) Case participants with a PSEN1 mutation (n=79) Case participants with a PSEN2 mutation (n=7)
Sex
 Female 3019 (60%) 46 (46%) 9 (60%) 32 (41%) 5 (71%)
 Male 2031 (40%) 55 (54%) 6 (40%) 47 (59%) 2 (29%)
Age, years 80 (73–86) 47 (40–55) 48 (43–55) 46 (38–54) 50 (46–55)
Participants with 1–2 copies of APOE ε4 1411 (28%) 34 (34%) 8 (53%) 20 (25%) 6 (86%)

Data are n, n (%), or median (IQR). The discovery cohort comprised non-Hispanic White participants included in case–control genome-wide association study analysis. Age is given as median age at the last healthy visit for control participants and median age at onset for case participants.